Claes Gustafsson | Co-Founder
ATUM BIO
As ATUM’s Co-Founder, Dr. Claes Gustafsson oversees most of the company’s external communications and is actively engaged in developing ATUM's technology platforms. Prior to co-founding ATUM in 2003, Claes managed key strategic teams at Maxygen Inc and worked as a scientist at Kosan Biosciences, and post-doctoral positions at UCSC and UCSF. He received his Ph.D. in Molecular Biology/Biochemistry from the University of Umeå, Sweden.
Appearances:
Festival of Biologics Day 1 @ 16:50
Optimizing Antibody Expression: ATUM’s Leap-In Transposase® Technology for Stable and Scalable Biologics Manufacturing
As the demand for high-quality biologics accelerates, biopharmaceutical developers face increasing pressure to optimize cell line development for speed, quality, stability, and scalability. ATUM’s Leap-In Transposase® technology is transforming the landscape of protein expression by enabling rapid, predictable, and high-yield stable cell line generation. Unlike traditional gene of interest integration methods, the Leap-In Transposase® system facilitates highly efficient transgene integration at transcriptionally active loci, leading to enhanced expression, improved genetic stability, and accelerated development timelines.In this presentation, we will showcase how the technology is empowering biopharma teams to achieve faster workflows while minimizing the need for labor-intensive single-cell cloning. We will present case studies demonstrating its impact across monoclonal antibodies, multispecifics, and novel therapeutic proteins, highlighting significant improvements in titers, scalability, and manufacturability. Furthermore, we will discuss its seamless integration with CHO and HEK cell systems, making it an ideal solution for both early-stage discovery and commercial-scale production.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events